𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pituitary tropic hormone studies and morphologic observations in carcinoma of the prostate

✍ Scribed by Andrew Dekker; Agnes B. Russfield

Publisher
John Wiley and Sons
Year
1963
Tongue
English
Weight
591 KB
Volume
16
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prognostic factors in metastatic and hor
Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate
✍ William R. Berry; John Laszlo; Edwin Cox; Ann Walker; David Paulson πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 English βš– 968 KB

Eighty-eight patients with hormone-resistant Stage IV prostate cancer were treated with a five-drug chemotherapy program. Patient demographic data, prior therapy, symptoms, extent of disease, and laboratory studies were analyzed statistically to evaluate the association of these parameters with surv

Phase II study of the oral cyclophospham
Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients
✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. ChrΓ©tien; Sy πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 413 KB πŸ‘ 2 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum

Bone fractures associated with luteinizi
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
✍ Murphy F. Townsend; W. Holt Sanders; Robert O. Northway; Sam D. Graham Jr. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 78 KB πŸ‘ 2 views

## Background: Luteinizing hormone-releasing hormone agonists (lhrh-a) have become an established treatment for certain patients with prostate carcinoma. lhrh-a are known to decrease bone mineral density. the purpose of this study was to determine the risk of bone fracture in men receiving lhrh-a f

Serum testosterone and sex hormone-bindi
Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma : A longitudinal study
✍ Ritva HeikkilΓ€; Kimmo Aho; Markku HeliΓΆvaara; Matti Hakama; Jukka Marniemi; Antt πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 60 KB πŸ‘ 2 views

## BACKGROUND. It has been hypothesized that high androgen levels are determinants of prostate carcinoma. ## METHODS. Serum concentrations of testosterone, sex hormone-binding globulin (SHBG), and androstenedione were analyzed to determine their role as predictors of prostate carcinoma in a lon

The dynamics of prostate specific antige
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma : An analysis of Cancer and Leukemia Group B Study 9181 of megestrol acetate
✍ Robin T. Vollmer; Nancy A. Dawson; Nicholas J. Vogelzang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 2 views

## BACKGROUND. Although many physicians measure serum prostate specific antigen (PSA) during the follow-up of patients with hormone refractory prostate carcinoma (HRPC), little has been done to formalize the determination of how these serial values of PSA impact on prognosis. To understand HRPC fu